| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5694628 | European Urology | 2017 | 13 Pages |
Abstract
In men with a rise in their PSA levels after prior local treatment for prostate cancer only, it is important to balance overtreatment against further progression of the disease since survival and quality of life may never be affected in many of these patients. For patients diagnosed with metastatic castrate-resistant prostate cancer, several new drugs have become available which may provide a clear survival benefit but the optimal choice will have to be made on an individual basis.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Philip Cornford, Joaquim Bellmunt, Michel Bolla, Erik Briers, Maria De Santis, Tobias Gross, Ann M. Henry, Steven Joniau, Thomas B. Lam, Malcolm D. Mason, Henk G. van der Poel, Theo H. van der Kwast, Olivier Rouvière, Thomas Wiegel, Nicolas Mottet,